Resources
9 Results (showing 1 - 9)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/26/2023 (updated 3/26/2024)
During this session, the Rural Behavioral Health Workforce Centers (RBHWCs) shared their collaborative project: a central resource hub for new workers looking to join the behavioral health workforce and a marketing campaign centering the value and roles of peer supports.
Posted 6/3/2022 (updated 3/27/2024)
… This presentation highlighted The Health Wagon’s Rural Communities Opioid Response program, … that aims to reduce the morbidity and mortality of substance use disorder (SUD), including opioid use … serves high-risk counties experiencing increasing rates of morbidity and mortality from what the Appalachian Regional …
Posted 6/6/2022 (updated 3/27/2024)
… The National CLAS Standards are a set of 15 action steps intended to advance health equity, improve quality, and help eliminate health … services. This session provided a general overview of the importance of cultural and linguistic services in …
Posted 6/7/2022 (updated 3/27/2024)
Celebrating RCORP Past and Present: A Look Into the Program’s History, Outcomes, and Future
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 2/28/2023 (updated 3/27/2024)
In November 2022, the FDA issued a letter providing information on the severe ulcerations that can occur from repeated xylazine exposure, withdrawal symptoms, and the interference xylazine can cause on successful treatment. The FDA continues to investigate the source of xylazine in the illicit drug supply. Health care professionals are strongly encouraged to report events in humans associated with xylazine exposure.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Supreme Court Room on Wednesday, March 5, 2020, at 2:30 PM
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence